ホームページ Protein Tyrosine Kinase c-Met inhibitor - VEGFR inhibitor - FLT3 inhibitor - c-Kit inhibitor - PDGFR inhibitor Foretinib For research use only.

Foretinib

別名：GSK1363089, EXEL-2880, XL-880, GSK089

Foretinib is an ATP-competitive inhibitor of HGFR and VEGFR, mostly for Met (c-Met) and KDR with IC50 of 0.4 nM and 0.9 nM in cell-free assays. Less potent against Ron, Flt-1/3/4, Kit (c-Kit), PDGFRα/β and Tie-2, and little activity to FGFR1 and EGFR. Phase 2.

Foretinib化学構造

CAS No. 849217-64-7

サイズ 価格(税別) 在庫状況
10mM (1mL in DMSO) JPY 42900 国内在庫あり
JPY 25500 国内在庫あり
JPY 104500 国内在庫あり
JPY 448500 国内在庫なし(納期7~10日)

代表番号: 045-509-1970|電子メール：[email protected]
よく尋ねられる質問

文献中Selleckの製品使用例（93）

製品安全説明書

現在のバッチを見る： 純度： 99.94%
99.94

Foretinib関連製品

シグナル伝達経路

c-Met Signaling Pathways

c-Metシグナル伝達経路

c-Met阻害剤の選択性比較

Cell Data

Cell Lines Assay Type Concentration Incubation Time 活性情報 PMID
U251 Function Assay 100/300/900 nM 24 h abrogates migration and invasion of glioma cells in a dose dependent manner 24658326
SF188 Function Assay 100/300/900 nM 24 h abrogates migration and invasion of glioma cells in a dose dependent manner 24658326
A172 Growth Inhibition Assay 100/300/900 nM 48 h reduces cell survival at 900 nM significantly 24658326
U251 Growth Inhibition Assay 100/300/900 nM 48 h reduces cell survival at 900 nM significantly 24658326
SF188 Growth Inhibition Assay 100/300/900 nM 48 h reduces cell survival at 900 nM significantly 24658326
SF188 Function Assay 100/300/900 nM 28 h induces PARP cleavage 24658326
U251 Function Assay 100/300/900 nM 28 h induces PARP cleavage 24658326
SF188 Function Assay 100/300/900 nM 1 h decreases Akt phosphorylation in a concentration dependent manner 24658326
A172 Function Assay 100/300/900 nM 1 h decreases Akt phosphorylation in a concentration dependent manner 24658326
U251 Function Assay 100/300/900 nM 1 h decreases Akt phosphorylation in a concentration dependent manner 24658326
SF188 Function Assay 100/300/900 nM 1 h inhibits the activity of Axl, Tyro3 24658326
A172 Function Assay 100/300/900 nM 1 h inhibits the activity of Axl, Tyro3 24658326
U251 Function Assay 100/300/900 nM 1 h inhibits the activity of Axl, Tyro3 24658326
SF188 Function Assay 100/300/900 nM 1 h inhibits the phosphorylation of MerTK  24658326
A172 Function Assay 100/300/900 nM 1 h inhibits the phosphorylation of MerTK  24658326
U251 Function Assay 100/300/900 nM 1 h inhibits the phosphorylation of MerTK  24658326
Daoy  Growth Inhibition Assay 0.5/1/2.5 μM 24-96 h inhibits cell growth in a dose dependent manner 25391241
Daoy  Apoptosis Assay 1 μM 24 h induces apoptosis 25391241
ONS76 Function Assay 0.5/1/2.5 μM 24 h inhibits HGF-mediated migration and invasion 25391241
Daoy  Function Assay 0.5/1/2.5 μM 24 h inhibits HGF-mediated migration and invasion 25391241
ONS76 Function Assay 0.5/1/2.5 μM 24 h inhibits the HGF-induced cMET pathway activation 25391241
Daoy  Function Assay 0.5/1/2.5 μM 24 h inhibits the HGF-induced cMET pathway activation 25391241
A172 Function Assay 100/300/900 nM 24 h abrogates migration and invasion of glioma cells in a dose dependent manner 24658326
Ba/F3 Cell Viability Assay 0.0001-10 μM 72 h inhibits cell growth in a dose dependent manner 24218589
HCC78 Cell Viability Assay 0.01-10 μM 72 h inhibits cell growth in a dose dependent manner 24218589
SK-HEP1 Cell Viability Assay 0.25-1.5 μM 24 h inhibits cell growth in a dose dependent manner 22187171
SK-HEP2 Function Assay 1 μM 24 h blocks HGF-induced cell motility 22187171
SK-HEP2 Function Assay 1 μM 24 h causes G2/M phase arrest with reduction in the G0/G1 and S phases 22187171
MKN-45  Growth Inhibition Assay 0.01-10 μM 5 d IC50=8 nM 21655918
KATO-III Growth Inhibition Assay 0.01-10 μM 5 d IC50=30 nM 21655918
MKN-45  Function Assay 1 μM 24 h inhibits phosphorylation of MET, Akt, and ERK1/2 in MKN-45 21655918
KATO-III Function Assay 1 μM 24 h inhibits phosphorylation of MET, Akt, and ERK1/2 in MKN-45 21655918
HCC827 Apoptosis assay 0.01 to 1 uM 72 hrs Induction of apoptosis in gefitinib resistant human HCC827 cells at 0.01 to 1 uM after 72 hrs by annexin V-FITC-propidium iodide staining-based flow cytometry method relative to control 28787156
HCC827 Function assay 0.1 to 0.5 uM 72 hrs Inhibition of MET phosphorylation at Tyr1234/1235 in gefitinib resistant human HCC827 cells at 0.1 to 0.5 uM after 72 hrs by Western blotting method 28787156
HCC827 Function assay 0.1 to 0.5 uM 72 hrs Downregulation of SMO expression in gefitinib resistant human HCC827 cells at 0.1 to 0.5 uM after 72 hrs by Western blotting method 28787156
HCC827 Function assay 0.1 to 0.5 uM 72 hrs Inhibition of MET in gefitinib resistant human HCC827 cells assessed as decrease in MAPK44/42 phosphorylation at Thr202/Tyr204 at 0.1 to 0.5 uM after 72 hrs by Western blotting method 28787156
HCC827 Function assay 0.1 to 0.5 uM 72 hrs Inhibition of MET in gefitinib resistant human HCC827 cells assessed as decrease in AKT phosphorylation at Ser473 at 0.1 to 0.5 uM after 72 hrs by Western blotting method 28787156
HCC827 Function assay 0.1 to 0.5 uM 72 hrs Inhibition of MET/SMO V404M mutant in gefitinib resistant human HCC827 cells assessed as decrease in vimentin expression at 0.1 to 0.5 uM after 72 hrs by Western blotting method 28787156
NCI-H1993 Function assay 1 uM 4 hrs Inhibition of c-MET D1228V mutant in CRISPR/Cas9 modified human NCI-H1993 cells assessed as reduction in AKT phosphorylation at 1 uM after 4 hrs by Western blot analysis 31531204
NCI-H1993 Function assay 1 uM 4 hrs Inhibition of c-Met phosphorylation in human NCI-H1993 cells at 1 uM after 4 hrs by Western blot analysis 31531204
NCI-1993 Function assay 1 uM 4 hrs Inhibition of c-MET in human NCI-1993 cells assessed as reduction in AKT phosphorylation at 1 uM after 4 hrs by Western blot analysis 31531204
NCI-H1993 Function assay 1 uM 4 hrs Inhibition of c-Met D1228V mutant phosphorylation in CRISPR/Cas9 modified human NCI-H1993 cells at 1 uM after 4 hrs by Western blot analysis 31531204
HCC827 Antiproliferative assay 72 hrs Antiproliferative activity against gefitinib resistant EGFR-mutated human HCC827 cells after 72 hrs by MTT assay, IC50 = 0.5 μM. 28787156
HCC827 Antitumor assay 15 mg/kg Antitumor activity against gefitinib resistant human HCC827 cells xenografted in balb/c athymic nu/nu mouse assessed as decrease in tumor size at 15 mg/kg/day, po 28787156
HCC827 Antitumor assay 20 mg/kg Antitumor activity against gefitinib resistant human HCC827 cells xenografted in balb/c athymic nu/nu mouse assessed as decrease in tumor size at 20 mg/kg/day, po 28787156
HCC827 Antitumor assay 20 mg/kg Antitumor activity against gefitinib resistant human HCC827 cells xenografted in balb/c athymic nu/nu mouse assessed as decrease in tumor size at 20 mg/kg/day, po in presence of gefitinib 28787156
HCC827 Antitumor assay 20 mg/kg Antitumor activity against gefitinib resistant human HCC827 cells xenografted in balb/c athymic nu/nu mouse assessed as decrease in tumor size at 20 mg/kg/day, po in presence of osimertinib 28787156
MKN45 Cytotoxicity assay 72 hrs Cytotoxicity against c-Met-dependent human MKN45 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50 = 0.03 μM. 23628470
A549 Cytotoxicity assay 72 hrs Cytotoxicity against c-Met-dependent human A549 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50 = 0.08 μM. 23628470
HT-29 Cytotoxicity assay 72 hrs Cytotoxicity against c-Met-dependent human HT-29 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50 = 0.15 μM. 23628470
H460 Cytotoxicity assay 72 hrs Cytotoxicity against c-Met-independent human H460 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50 = 0.18 μM. 23628470
SMMC7721 Cytotoxicity assay 72 hrs Cytotoxicity against c-Met-dependent human SMMC7721 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50 = 0.44 μM. 23628470
U87MG Cytotoxicity assay 72 hrs Cytotoxicity against c-Met-dependent human U87MG cells assessed as growth inhibition after 72 hrs by MTT assay, IC50 = 0.9 μM. 23628470
MKN45 Cytotoxicity assay 72 hrs Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay, IC50 = 0.031 μM. 23644189
H460 Cytotoxicity assay 72 hrs Cytotoxicity against human H460 cells after 72 hrs by MTT assay, IC50 = 0.12 μM. 23644189
HT-29 Cytotoxicity assay 72 hrs Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay, IC50 = 0.18 μM. 23644189
SMMC7721 Cytotoxicity assay 72 hrs Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay, IC50 = 0.3 μM. 23644189
U87MG Cytotoxicity assay 72 hrs Cytotoxicity against human U87MG cells after 72 hrs by MTT assay, IC50 = 1.04 μM. 23644189
MKN45 Cytotoxicity assay 72 hrs Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay, IC50 = 0.023 μM. 23838381
A549 Cytotoxicity assay 72 hrs Cytotoxicity against human A549 cells after 72 hrs by DAPI staining-based fluorescence assay, IC50 = 0.029 μM. 23838381
HT-29 Cytotoxicity assay 72 hrs Cytotoxicity against human HT-29 cells after 72 hrs by DAPI staining-based fluorescence assay, IC50 = 0.165 μM. 23838381
A549 Cytotoxicity assay 72 hrs Cytotoxicity against human A549 cells after 72 hrs by MTT assay, IC50 = 0.17 μM. 23838381
NCI-H460 Cytotoxicity assay 72 hrs Cytotoxicity against human NCI-H460 cells after 72 hrs by MTT assay, IC50 = 0.21 μM. 23838381
HT-29 Cytotoxicity assay 72 hrs Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay, IC50 = 0.26 μM. 23838381
SMMC7721 Cytotoxicity assay 72 hrs Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay, IC50 = 0.32 μM. 23838381
U87MG Cytotoxicity assay 72 hrs Cytotoxicity against human U87MG cells after 72 hrs by MTT assay, IC50 = 0.47 μM. 23838381
MKN45 Cytotoxicity assay 72 hrs Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay, IC50 = 0.032 μM. 24012712
A549 Cytotoxicity assay 72 hrs Cytotoxicity against human A549 cells after 72 hrs by MTT assay, IC50 = 0.11 μM. 24012712
HT-29 Cytotoxicity assay 72 hrs Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay, IC50 = 0.19 μM. 24012712
H460 Cytotoxicity assay 72 hrs Cytotoxicity against human H460 cells after 72 hrs by MTT assay, IC50 = 0.21 μM. 24012712
U87MG Cytotoxicity assay 72 hrs Cytotoxicity against human U87MG cells after 72 hrs by MTT assay, IC50 = 1.08 μM. 24012712
MKN45 Cytotoxicity assay 72 hrs Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay, IC50 = 0.032 μM. 24485123
A549 Cytotoxicity assay 72 hrs Cytotoxicity against human A549 cells after 72 hrs by MTT assay, IC50 = 0.13 μM. 24485123
HT-29 Cytotoxicity assay 72 hrs Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay, IC50 = 0.16 μM. 24485123
H460 Cytotoxicity assay 72 hrs Cytotoxicity against human H460 cells after 72 hrs by MTT assay, IC50 = 0.19 μM. 24485123
U87MG Cytotoxicity assay 72 hrs Cytotoxicity against human U87MG cells after 72 hrs by MTT assay, IC50 = 1.1 μM. 24485123
MKN45 Cytotoxicity assay 72 hrs Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay, IC50 = 0.032 μM. 24882675
HT-29 Cytotoxicity assay 72 hrs Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay, IC50 = 0.19 μM. 24882675
H460 Cytotoxicity assay 72 hrs Cytotoxicity against human H460 cells after 72 hrs by MTT assay, IC50 = 0.21 μM. 24882675
MDA-MB-231 Cytotoxicity assay 72 hrs Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay, IC50 = 0.54 μM. 24882675
MKN45 Cytotoxicity assay 72 hrs Cytotoxicity against human MKN45 cells assessed as inhibition of cell growth after 72 hrs by MTT assay, IC50 = 0.032 μM. 24996144
A549 Cytotoxicity assay 72 hrs Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay, IC50 = 0.11 μM. 24996144
HT-29 Cytotoxicity assay 72 hrs Cytotoxicity against human HT-29 cells assessed as inhibition of cell growth after 72 hrs by MTT assay, IC50 = 0.19 μM. 24996144
H460 Cytotoxicity assay 72 hrs Cytotoxicity against human H460 cells assessed as inhibition of cell growth after 72 hrs by MTT assay, IC50 = 0.21 μM. 24996144
U87MG Cytotoxicity assay 72 hrs Cytotoxicity against human U87MG cells assessed as inhibition of cell growth after 72 hrs by MTT assay, IC50 = 1.08 μM. 24996144
MKN45 Antiproliferative assay 72 hrs Antiproliferative activity against human MKN45 cells assessed as inhibition of cell growth after 72 hrs by MTT assay, IC50 = 0.032 μM. 25282672
A549 Antiproliferative assay 72 hrs Antiproliferative activity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT assay, IC50 = 0.12 μM. 25282672
HT-29 Antiproliferative assay 72 hrs Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth after 72 hrs by MTT assay, IC50 = 0.19 μM. 25282672
H460 Antiproliferative assay 72 hrs Antiproliferative activity against human H460 cells assessed as inhibition of cell growth after 72 hrs by MTT assay, IC50 = 0.21 μM. 25282672
U87MG Antiproliferative assay 72 hrs Antiproliferative activity against human U87MG cells assessed as inhibition of cell growth after 72 hrs by MTT assay, IC50 = 1.02 μM. 25282672
MKN45 Cytotoxicity assay 72 hrs Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay, IC50 = 0.032 μM. 25438768
A549 Cytotoxicity assay 72 hrs Cytotoxicity against human A549 cells after 72 hrs by MTT assay, IC50 = 0.13 μM. 25438768
HT-29 Cytotoxicity assay 72 hrs Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay, IC50 = 0.16 μM. 25438768
H460 Cytotoxicity assay 72 hrs Cytotoxicity against human H460 cells after 72 hrs by MTT assay, IC50 = 0.19 μM. 25438768
U87MG Cytotoxicity assay 72 hrs Cytotoxicity against human U87MG cells after 72 hrs by MTT assay, IC50 = 0.92 μM. 25438768
HT-29 Cytotoxicity assay 72 hrs Cytotoxicity against human HT-29 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay, IC50 = 0.032 μM. 26169763
MKN45 Cytotoxicity assay 72 hrs Cytotoxicity against human MKN45 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay, IC50 = 0.12 μM. 26169763
A549 Cytotoxicity assay 72 hrs Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay, IC50 = 0.19 μM. 26169763
H460 Cytotoxicity assay 72 hrs Cytotoxicity against human H460 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay, IC50 = 0.21 μM. 26169763
PC3 Cytotoxicity assay 72 hrs Cytotoxicity against human PC3 cells after 72 hrs by MTT assay, IC50 = 0.39 μM. 26810712
A549 Cytotoxicity assay 72 hrs Cytotoxicity against human A549 cells after 72 hrs by MTT assay, IC50 = 0.64 μM. 26810712
MCF7 Cytotoxicity assay 72 hrs Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay, IC50 = 9.47 μM. 26810712
MKN45 Cytotoxicity assay 72 hrs Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay, IC50 = 0.023 μM. 26897090
A549 Cytotoxicity assay 72 hrs Cytotoxicity against human A549 cells after 72 hrs by MTT assay, IC50 = 0.17 μM. 26897090
HT-29 Cytotoxicity assay 72 hrs Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay, IC50 = 0.26 μM. 26897090
HT-29 Cytotoxicity assay 72 hrs Cytotoxicity against human HT-29 cells assessed as reduction in cell growth after 72 hrs by MTT assay, IC50 = 0.26 μM. 26923692
A549 Cytotoxicity assay 72 hrs Cytotoxicity against human A549 cells assessed as reduction in cell growth after 72 hrs by MTT assay, IC50 = 0.49 μM. 26923692
PC3 Cytotoxicity assay 72 hrs Cytotoxicity against human PC3 cells assessed as reduction in cell growth after 72 hrs by MTT assay, IC50 = 0.89 μM. 26923692
MCF7 Cytotoxicity assay 72 hrs Cytotoxicity against human MCF7 cells assessed as reduction in cell growth after 72 hrs by MTT assay, IC50 = 6.25 μM. 26923692
MKN45 Cytotoxicity assay 72 hrs Cytotoxicity against human MKN45 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50 = 0.032 μM. 26944614
A549 Cytotoxicity assay 72 hrs Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50 = 0.13 μM. 26944614
HT-29 Cytotoxicity assay 72 hrs Cytotoxicity against human HT-29 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50 = 0.16 μM. 26944614
H460 Cytotoxicity assay 72 hrs Cytotoxicity against human H460 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50 = 0.19 μM. 26944614
U87MG Cytotoxicity assay 72 hrs Cytotoxicity against human U87MG cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50 = 1.1 μM. 26944614
PC3 Cytotoxicity assay 72 hrs Cytotoxicity against human PC3 cells after 72 hrs by MTT assay, IC50 = 0.39 μM. 26964675
A549 Cytotoxicity assay 72 hrs Cytotoxicity against human A549 cells after 72 hrs by MTT assay, IC50 = 0.64 μM. 26964675
MCF7 Cytotoxicity assay 72 hrs Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay, IC50 = 9.47 μM. 26964675
BA/F3 Antiproliferative assay 72 hrs Antiproliferative activity against mouse BA/F3 cells expressing TPR-Met after 72 hrs by CCK8 assay, IC50 = 0.0092 μM. 27068889
MKN45 Cytotoxicity assay 72 hrs Cytotoxicity against human MKN45 cells measured after 72 hrs by MTT assay, IC50 = 0.032 μM. 27155466
A549 Cytotoxicity assay 72 hrs Cytotoxicity against human A549 cells measured after 72 hrs by MTT assay, IC50 = 0.11 μM. 27155466
HT-29 Cytotoxicity assay 72 hrs Cytotoxicity against human HT-29 cells measured after 72 hrs by MTT assay, IC50 = 0.19 μM. 27155466
H460 Cytotoxicity assay 72 hrs Cytotoxicity against human H460 cells measured after 72 hrs by MTT assay, IC50 = 0.21 μM. 27155466
MKN45 Cytotoxicity assay 72 hrs Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay, IC50 = 0.023 μM. 27187857
HT-29 Cytotoxicity assay 72 hrs Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay, IC50 = 0.17 μM. 27187857
A549 Cytotoxicity assay 72 hrs Cytotoxicity against human A549 cells after 72 hrs by MTT assay, IC50 = 0.26 μM. 27187857
MDA-MB-231 Cytotoxicity assay 72 hrs Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay, IC50 = 0.54 μM. 27187857
Sf9 Function assay 60 mins Inhibition of NH2-terminal His-tagged MET kinase domain (1051 to 1348 residues) (unknown origin) expressed in baculovirus infected Sf9 insect cells preincubated for 60 mins followed by (poly(Glu, Tyr) 4:1) substrate addition for 2 to 4 hrs by luciferase-c, IC50 = 0.0004 μM. 27299736
MKN45 Cytotoxicity assay 72 hrs Cytotoxicity against c-Met over-expressed human MKN45 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50 = 0.032 μM. 27490023
A549 Cytotoxicity assay 72 hrs Cytotoxicity against c-Met over-expressed human A549 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50 = 0.14 μM. 27490023
HT-29 Cytotoxicity assay 72 hrs Cytotoxicity against c-Met over-expressed human HT-29 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50 = 0.19 μM. 27490023
H460 Cytotoxicity assay 72 hrs Cytotoxicity against c-Met over-expressed human H460 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50 = 0.21 μM. 27490023
A549 Cytotoxicity assay 72 hrs Cytotoxicity against human A549 cells after 72 hrs by MTT assay, IC50 = 0.15 μM. 28011202
HT-29 Cytotoxicity assay 72 hrs Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay, IC50 = 0.25 μM. 28011202
MKN45 Cytotoxicity assay 72 hrs Cytotoxicity against human MKN45 cells after 72 hrs by MTT assay, IC50 = 0.32 μM. 28011202
HT-29 Cytotoxicity assay 72 hrs Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay, IC50 = 0.25 μM. 28384549
H460 Cytotoxicity assay 72 hrs Cytotoxicity against human H460 cells after 72 hrs by MTT assay, IC50 = 0.29 μM. 28384549
A549 Cytotoxicity assay 72 hrs Cytotoxicity against human A549 cells after 72 hrs by MTT assay, IC50 = 0.36 μM. 28384549
U87MG Cytotoxicity assay 72 hrs Cytotoxicity against human U87MG cells after 72 hrs by MTT assay, IC50 = 0.96 μM. 28384549
MKN45 Antiproliferative assay 72 hrs Antiproliferative activity against human MKN45 cells after 72 hrs by MTT assay, IC50 = 0.03 μM. 28716639
A549 Antiproliferative assay 72 hrs Antiproliferative activity against human A549 cells after 72 hrs by MTT assay, IC50 = 0.15 μM. 28716639
HT-29 Antiproliferative assay 72 hrs Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay, IC50 = 0.21 μM. 28716639
H460 Antiproliferative assay 72 hrs Antiproliferative activity against human H460 cells after 72 hrs by MTT assay, IC50 = 0.22 μM. 28716639
U87MG Antiproliferative assay 72 hrs Antiproliferative activity against human U87MG cells after 72 hrs by MTT assay, IC50 = 0.96 μM. 28716639
PC3 Cytotoxicity assay 72 hrs Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50 = 1.48 μM. 29107421
A549 Cytotoxicity assay 72 hrs Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50 = 1.74 μM. 29107421
HepG2 Cytotoxicity assay 72 hrs Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50 = 2.88 μM. 29107421
MCF7 Cytotoxicity assay 72 hrs Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50 = 3.92 μM. 29107421
HT-29 Antiproliferative assay 72 hrs Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay, IC50 = 0.26 μM. 29197731
NCI-H460 Antiproliferative assay 72 hrs Antiproliferative activity against human NCI-H460 cells after 72 hrs by MTT assay, IC50 = 0.28 μM. 29197731
A549 Antiproliferative assay 72 hrs Antiproliferative activity against human A549 cells after 72 hrs by MTT assay, IC50 = 0.32 μM. 29197731
U87MG Antiproliferative assay 72 hrs Antiproliferative activity against human U87MG cells after 72 hrs by MTT assay, IC50 = 0.91 μM. 29197731
HepG2 Cytotoxicity assay 72 hrs Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay, IC50 = 2.27 μM. 29203143
MCF7 Cytotoxicity assay 72 hrs Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay, IC50 = 2.76 μM. 29203143
A549 Cytotoxicity assay 72 hrs Cytotoxicity against human A549 cells after 72 hrs by MTT assay, IC50 = 3.13 μM. 29203143
PC3 Antiproliferative assay 72 hrs Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay, IC50 = 0.39 μM. 29331754
A549 Antiproliferative assay 72 hrs Antiproliferative activity against human A549 cells after 72 hrs by MTT assay, IC50 = 0.64 μM. 29331754
MCF7 Antiproliferative assay 72 hrs Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay, IC50 = 9.47 μM. 29331754
A549 Antiproliferative assay 72 hrs Antiproliferative activity against human A549 cells after 72 hrs by MTT assay, IC50 = 0.32 μM. 30216852
HepG2 Antiproliferative assay 72 hrs Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay, IC50 = 0.48 μM. 30216852
MCF7 Antiproliferative assay 72 hrs Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay, IC50 = 0.76 μM. 30216852
MKN45 Antiproliferative assay 72 hrs Antiproliferative activity against human MKN45 cells after 72 hrs by MTT assay, IC50 = 0.0023 μM. 30248654
EBC1 Antiproliferative assay 72 hrs Antiproliferative activity against human EBC1 cells after 72 hrs by MTT assay, IC50 = 0.0048 μM. 30248654
SNU5 Antiproliferative assay 72 hrs Antiproliferative activity against human SNU5 cells after 72 hrs by MTT assay, IC50 = 0.0089 μM. 30248654
BAF3 Function assay 72 hrs Inhibition of TPR-tagged met (unknown origin) expressed in mouse BAF3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay, IC50 = 0.0092 μM. 30248654
NCI-H460 Antiproliferative assay 72 hrs Antiproliferative activity against human NCI-H460 cells after 72 hrs by MTT assay, IC50 = 0.0396 μM. 30248654
MKN45 Cytotoxicity assay 72 hrs Cytotoxicity in human MKN45 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay, IC50 = 0.041 μM. 31079967
NCI-H460 Cytotoxicity assay 72 hrs Cytotoxicity in human NCI-H460 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay, IC50 = 0.18 μM. 31079967
HT-29 Cytotoxicity assay 72 hrs Cytotoxicity in human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay, IC50 = 0.22 μM. 31079967
MDA-MB-231 Cytotoxicity assay 72 hrs Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay, IC50 = 0.52 μM. 31079967
sf21 Function assay 60 mins Inhibition of wild type N-terminal NH-tagged and avi-tagged dephosphorylated c-MET (956 to 1390 residues) (unknown origin) expressed in sf21 cells using poly (Glu,Tyr) as substrate measured after 60 mins by ADP-Glo kinase assay, IC50 = 0.002512 μM. 31531204
sf21 Function assay 60 mins Inhibition of N-terminal NH-tagged and avi-tagged dephosphorylated c-MET D1228V mutant (956 to 1390 residues) (unknown origin) expressed in sf21 cells using poly (Glu,Tyr) as substrate measured after 60 mins by ADP-Glo kinase assay, IC50 = 0.002512 μM. 31531204
NCI-H1993 Growth inhibition assay 3 days Growth inhibition of CRISPR/Cas9 modified human NCI-H1993 cells harboring cMET D1228V mutant incubated for 3 days by cell titer-glo luminescent cell viability assay, GI50 = 0.05248 μM. 31531204
NCI-H1993 Growth inhibition assay 3 days Growth inhibition of wild type human NCI-H1993 cells incubated for 3 days by cell titer-glo luminescent cell viability assay, GI50 = 0.06166 μM. 31531204
NCI-H1993 Function assay 4 hrs Inhibition of c-Met phosphorylation at Tyr 1234/Tyr1235 residues in human NCI-H1993 cells incubated for 4 hrs by HTRF assay, IC50 = 0.2138 μM. 31531204
NCI-H1993 Function assay 4 hrs Inhibition of c-MET D1228V mutant phosphorylation at Tyr1234/Tyr1235 residues in CRISPR/Cas9 modified human NCI-H1993 cells incubated for 4 hrs by HTRF assay, IC50 = 0.2138 μM. 31531204
A549 Antiproliferative assay 72 hrs Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50 = 2.4 μM. 31546197
MCF7 Antiproliferative assay 72 hrs Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50 = 2.4 μM. 31546197
HepG2 Antiproliferative assay 72 hrs Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay, IC50 = 2.4 μM. 31546197
MKN45 Cytotoxicity assay 72 hrs Cytotoxicity against human MKN45 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay, IC50 = 0.2 μM. 31629631
H460 Cytotoxicity assay 72 hrs Cytotoxicity against human H460 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay, IC50 = 1.14 μM. 31629631
A549 Cytotoxicity assay 72 hrs Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay, IC50 = 1.49 μM. 31629631
HT-29 Cytotoxicity assay 72 hrs Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay, IC50 = 1.76 μM. 31629631
U87MG Cytotoxicity assay 72 hrs Cytotoxicity against human U87MG cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay, IC50 = 2.17 μM. 31629631
H1648 Growth Inhibition Assay IC50=1.28 ±0.12 μM 21252284
H1573 Growth Inhibition Assay IC50=1.62 ± 0.05 μM 21252284
H596 Growth Inhibition Assay IC50=1.21 ± 0.17 μM 21252284
HOP92 Growth Inhibition Assay IC50=0.81 ± 0.29 μM 21252284
H69 Growth Inhibition Assay IC50=1.18 ± 0.08 μM 21252284
H1975 Growth Inhibition Assay IC50=1.39 ± 0.33 μM 21252284
SCC15 Growth Inhibition Assay IC50=0.63 ± 0.04 μM 21252284
HN5 Growth Inhibition Assay IC50=0.65 ± 0.26 μM 21252284
MKN45 Cytotoxicity assay Cytotoxicity against human MKN45 cells, IC50 = 0.008 μM. 23838381
BA/F3 Function assay Inhibition of ROS1 (unknown origin) expressed in mouse BA/F3 cells, IC50 = 0.01 μM. 25461320
BT474 Function assay Inhibition of AXL in lapatinib-sensitive human BT474 cells, IC50 = 0.1 μM. 26555154
MKN45 Cytotoxicity assay Cytotoxicity against human MKN45 cells, IC50 = 0.008 μM. 27187857
HT-29 Cytotoxicity assay Cytotoxicity against human HT-29 cells, IC50 = 0.029 μM. 27187857
A549 Cytotoxicity assay Cytotoxicity against human A549 cells, IC50 = 0.165 μM. 27187857
HCC827 Function assay Displacement of [3H]-cyclopamine from SMO V404M mutant in gefitinib resistant human HCC827 cells by scintillation counting, Ki = 0.0668 μM. 28787156
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells 29435139
DAOY qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells 29435139
NB-EBc1 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells 29435139
U-2 OS qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells 29435139
Saos-2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells 29435139
NB1643 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells 29435139
LAN-5 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells 29435139
BT-12 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells 29435139
Rh18 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells 29435139
MG 63 (6-TG R) qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells 29435139
fibroblast cells qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells 29435139
Rh30 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells 29435139
Rh41 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells 29435139
NB1643 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells 29435139
A673 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) 29435139
SK-N-MC qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells 29435139
BT-12 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells 29435139
LAN-5 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells 29435139
DAOY qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells 29435139
NB-EBc1 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells 29435139
SJ-GBM2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells 29435139
BT-37 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells 29435139
TC32 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells 29435139
MG 63 (6-TG R) qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells 29435139
fibroblast cells qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells 29435139
U-2 OS qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells 29435139
Rh41 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells 29435139
RD qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells 29435139
Rh18 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells 29435139
Saos-2 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells 29435139
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells 29435139
SK-N-SH qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells 29435139
sf21 Function assay Binding affinity to wild type N-terminal NH-tagged and avi-tagged dephosphorylated c-MET (956 to 1390 residues) (unknown origin) expressed in sf21 cells by SPR analysis 31531204
sf21 Function assay Binding affinity to N-terminal NH-tagged and avi-tagged dephosphorylated c-MET D1228V mutant (956 to 1390 residues) (unknown origin) expressed in sf21 cells by SPR analysis 31531204
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明 Foretinib is an ATP-competitive inhibitor of HGFR and VEGFR, mostly for Met (c-Met) and KDR with IC50 of 0.4 nM and 0.9 nM in cell-free assays. Less potent against Ron, Flt-1/3/4, Kit (c-Kit), PDGFRα/β and Tie-2, and little activity to FGFR1 and EGFR. Phase 2.
Targets
Met [1]
(Cell-free assay)		 KDR [1]
(Cell-free assay)		 Tie-2 [1]
(Cell-free assay)		 VEGFR3/FLT4 [1]
(Cell-free assay)		 RON [1]
(Cell-free assay)		 もっとクリックする
0.4 nM 0.86 nM 1.1 nM 2.8 nM 3 nM
In Vitro
In vitro XL880 inhibits HGF receptor family tyrosine kinases with IC50 values of 0.4 nM for Met and 3 nM for Ron. XL880 also inhibits KDR, Flt-1, and Flt-4 with IC50 values of 0.9 nM, 6.8 nM and 2.8 nM, respectively. XL880 inhibits colony growth of B16F10, A549 and HT29 cells with IC50 of 40 nM, 29 nM and 165 nM, respectively. [1] A recent study indicates XL880 affects cell growth differently in gastric cancer cell lines MKN-45 and KATO-III. XL880 inhibits phosphorylation of MET and downstream signaling molecules in MKN-45 cells, while targets GFGR2 in KATO-III cells. [2]
Kinase Assay Kinase Inhibition Assay
Kinase inhibition is investigated using one of three assay formats: [33P]phosphoryl transfer, luciferase-coupled chemiluminescence, or AlphaScreen tyrosine kinase technology. IC50s are calculated by nonlinear regression analysis using XLFit.33P -Phosphoryl Transfer Kinase Assay Reactions are performed in 384-well white, clear bottom, high-binding microtiter plates (Greiner, Monroe, NC). Plates are coated with 2 μg/well of protein or peptide substrate in a 50 μL volume of coating buffer contained 40 μg/mL substrate (poly(Glu, Tyr) 4:1, 22.5 mM Na2CO3, 27.5 mM NaHCO3, 50 mM NaCl and 3 mM NaN 3. Coated plates are washed once with 50 μL of assay buffer following overnight incubation at room temperature (RT). Test compounds and enzymes are combined with 33P-γ-ATP (3.3 μCi/nmol) in a total volume of 20 μL. The reaction mixture is incubated at RT for 2 hours and terminated by aspiration. The microtiter plates are subsequently washed 6 times with 0.05% Tween-PBS buffer (PBST). Scintillation fluid (50 μL/well) is added and incorporated 33P is measured by liquid scintillation spectrometry using a MicroBeta scintillation counter.Luciferase-Coupled Chemiluminescence Assay Reactions are conducted in 384-well white, medium binding microtiter plates (Greiner). In a first step enzyme and compound are combined and incubated for 60 minutes; reactions are initiated by addition of ATP and peptide substrate (poly(Glu, Tyr) 4:1) in a final voume of 20 μL, and incubated at RT for 2-4 hours. Following the kinase reaction, a 20 μL aliquot of Kinase Glo (Promega, Madison, WI) is added and luminescence signal is measured using a Victor plate reader. Total ATP consumption is limited to 50%. AlphaScreenTM Tyrosine Kinase Assay Donor beads coated with streptavidin and acceptor beads coated with PY100 anti-phosphotyrosine antibody are used. Biotinylated poly(Glu,Tyr) 4:1 is used as the substrate. Substrate phosphorylation is measured by addition of donor/acceptor beads by luminescence following donor-acceptor bead complex formation. Kinase and test compounds are combined and preincubated for 60 minutes, followed by addition of ATP, and biotinylated poly(Glu, Tyr) in a total volume of 20 μL in 384-well white, medium binding microtiter plates (Greiner). Reaction mixtures are incubated for 1 hour at room temperature. Reactions are quenched by addition of 10 μL of 15-30 μg/mL AlphaScreen bead suspension containing 75 mM Hepes, pH 7.4, 300 mM NaCl, 120 mM EDTA, 0.3% BSA and 0.03% Tween-20. After 2-16 hours incubation at room temperature plates are read using an AlphaQuest reader.
細胞実験 細胞株 B16F10, A549, and HT29 cells
濃度 40 nM
反応時間 12 to 14 days
実験の流れ

B16F10, A549, and HT29 cells (1.2× 103 per well) are mixed with soft agar and seeded in a 96-well plate containing 10% FBS and EXEL-2880 over a base agar layer. For normoxic conditions, the plates are incubated (37°C) for 12 to 14 days in 21% oxygen, 5% CO2, and 74% nitrogen, whereas incubation (37 °C) under hypoxic conditions is done in a hypoxia chamber in 1% oxygen, 5% CO2, and 94% nitrogen. The number of colonies is evaluated under each condition following addition of 50% Alamar Blue and fluorescence detection.
実験結果図 Methods Biomarkers 結果図 PMID
Western blot p-Met / Met / p-Akt / Akt p-MDM2 / p53 / PUMA pROS1 / tROS1 / pSHP2 / pERK / ERK 29854314
Growth inhibition assay Cell viability 29854314
In Vivo
In Vivo A single 100 mg/kg oral gavage dose of XL880 results in substantial inhibition of phosphorylation of B16F10 tumor Met and ligand (e.g., HGFor VEGF)-induced receptor phosphorylation of Met in liver and Flk-1/KDR in lung, which both persisted through 24 hours. Treatment with XL880 (30-100 mg/kg, once daily, oral gavage) results in reduction in tumor burden. The lung surface tumor burden is reduced by 50% and 58% following treatment with 30 and 100 mg/kg XL880, respectively. XL880 treatment of mice bearing B16F10 solid tumors also results in dose-dependent tumor growth inhibition of 64% and 87% at 30 and 100 mg/kg, respectively. For both studies, administration of XL880 is well tolerated with no significant body weight loss. [1] XL880 is developed to target abnormal signaling of HGF through Met and simultaneously target several receptors tyrosine kinase involved in tumor angiogenesis. XL880 caused tumor hemorrhage and necrosis in human xenografts within 2 to 4 hours, and maximal tumornecrosis is observed at 96 hours (after five daily doses), resulting in complete regression. [3]
動物実験 動物モデル B16F10 tumor cells (2 × 10 5) are implanted via i.v. tail vein injection into athymic nude mice (NCr or BALB/c) 5 to 8 weeks old
投与量 100 mg/kg
投与経路 Administered via oral gavage
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00920192 Completed
Carcinoma Hepatocellular
GlaxoSmithKline
 August 12 2009 Phase 1
NCT00742261 Completed
Solid Tumours
GlaxoSmithKline
 August 11 2008 Phase 1
NCT00725764 Completed
Neoplasms Head and Neck
GlaxoSmithKline
 August 27 2007 Phase 2
NCT00725712 Completed
Neoplasms Gastrointestinal Tract
GlaxoSmithKline
 March 31 2007 Phase 2
NCT00743067 Completed
Solid Tumours
GlaxoSmithKline
 August 9 2006 Phase 1

化学情報

分子量 632.65 化学式

C34H34F2N4O6
CAS No. 849217-64-7 SDF Download Foretinib SDFをダウンロードする
Smiles COC1=CC2=C(C=CN=C2C=C1OCCCN3CCOCC3)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F
保管

In vitro
Batch:

DMSO : 100 mg/mL ( (158.06 mM)； 吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Water : Insoluble

Ethanol : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量 濃度 体積 分子量

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

mg/kg g μL 匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO % % Tween 80 % ddH2O
%DMSO %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH2O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください
Tags: Foretinibを買う | Foretinib ic50 | Foretinib供給者 | Foretinibを購入する | Foretinib費用 | Foretinib生産者 | オーダーForetinib | Foretinib化学構造 | Foretinib分子量 | Foretinib代理店